Hepatic Microsomal Enzyme Research Articles

Intestinal Metabolism of Crocin and a Pharmacokinetics and Pharmacodynamics Study in the Chronic Social Defeat Stress Mouse Model.

Orally administered crocin rapidly and efficiently rescues depressive-like behaviors in depression models; however, crocin levels in the circulatory and central nervous systems are rather low. The underlying mechanism responsible for the inconsistency between pharmacokinetics and pharmacodynamics is unknown. To identify the active metabolites and clarify the underlying mechanisms, the pharmacokinetics and metabolic effects of the gut flora and hepatic and intestinal microsomes on crocin were examined, and the pharmacodynamics of crocin and its major metabolite, crocetin, were also evaluated in both normal and pseudo germ-free mice subjected to chronic social defeat stress. The results showed that oral administration of 300 mg/kg crocin significantly improved the depression-like behaviors of chronic social defeat stress mice, although the levels of crocin in the circulatory system were rather low (Cmax = 43.5 ± 8.6 μg/L; AUC = 151 ± 20.8 μg·h/L). However, the primary metabolite of crocetin was much more abundant in vivo (Cmax = 4662.5 ± 586.1 μg/L; AUC = 33,451.9 ± 3323.6 μg·h/L). Orally administered crocin was primarily metabolized into crocetin by the gut flora instead of hepatic or intestinal microsomal enzymes, and less than 10% of crocin was transformed into crocetin in the liver or intestinal microsomes. Inhibition of the gut flora dramatically reduced the production of and in vivo exposure to crocetin, and the rapid antidepressant effect of crocin disappeared. Moreover, crocetin showed rapid antidepressant effects similar to those of crocin, and the effects were independent of the gut flora. In conclusion, the metabolic transformation of crocin to crocetin primarily contributes to the rapid antidepressant effects of crocin and is dependent on the gut flora.

Mode of action analysis for fluxapyroxad-induced rat liver tumour formation: evidence for activation of the constitutive androstane receptor and assessment of human relevance

The fungicide fluxapyroxad (BAS 700 F) has been shown to significantly increase the incidence of liver tumours in male Wistar rats at dietary levels of 1500 and 3000 ppm and in female rats at a dietary level of 3000 ppm via a non-genotoxic mechanism. In order to elucidate the mode of action (MOA) for fluxapyroxad-induced rat liver tumour formation a series of in vivo and in vitro investigative studies were undertaken. The treatment of male and female Wistar rats with diets containing 0 (control), 50, 250, 1500 and 3000 ppm fluxapyroxad for 1, 3, 7 and 14 days resulted in a dose-dependent increases in relative weight at 1500 and 3000 ppm from day 3 onwards in both sexes, with an increase in relative liver weight being also observed in male rats given 250 ppm fluxapyroxad for 14 days. Examination of liver sections revealed a centrilobular hepatocyte hypertrophy in some fluxapyroxad treated male and female rats. Hepatocyte replicative DNA synthesis (RDS) was significantly increased in male rats given 1500 and 3000 ppm fluxapyroxad for 3 and 7 days and in female rats given 50–3000 ppm fluxapyroxad for 7 days and 250–3000 ppm fluxapyroxad for 3 and 14 days; the maximal increases in RDS in both sexes being observed after 7 days treatment. The treatment of male and female Wistar rats with 250–3000 ppm fluxapyroxad for 14 days resulted in significant increases in hepatic microsomal total cytochrome P450 (CYP) content and CYP2B subfamily-dependent enzyme activities. Male Wistar rat hepatocytes were treated with control medium and medium containing 1–100 μM fluxapyroxad or 500 μM sodium phenobarbital (NaPB) for 4 days. Treatment with fluxapyroxad and NaPB increased CYP2B and CYP3A enzyme activities and mRNA levels but had little effect on markers of CYP1A and CYP4A subfamily enzymes and of the peroxisomal fatty acid β-oxidation cycle. Hepatocyte RDS was significantly increased by treatment with fluxapyroxad, NaPB and 25 ng/ml epidermal growth factor (EGF). The treatment of hepatocytes from two male human donors with 1–100 μM fluxapyroxad or 500 μM NaPB for 4 days resulted in some increases in CYP2B and CYP3A enzyme activities and CYP mRNA levels but had no effect on hepatocyte RDS, whereas treatment with EGF resulted in significant increase in RDS in both human hepatocyte preparations. Hepatocytes from male Sprague-Dawley wild type (WT) and constitutive androstane receptor (CAR) knockout (CAR KO) rats were treated with control medium and medium containing 1–16 μM fluxapyroxad or 500 μM NaPB for 4 days. While both fluxapyroxad and NaPB increased CYP2B enzyme activities and mRNA levels in WT hepatocytes, only minor effects were observed in CAR KO rat hepatocytes. Treatment with both fluxapyroxad and NaPB only increased RDS in WT and not in CAR KO rat hepatocytes, whereas treatment with EGF increased RDS in both WT and CAR KO rat hepatocytes. In conclusion, a series of in vivo and in vitro investigative studies have demonstrated that fluxapyroxad is a CAR activator in rat liver, with similar properties to the prototypical CAR activator phenobarbital. A robust MOA for fluxapyroxad-induced rat liver tumour formation has been established. Based on the lack of effect of fluxapyroxad on RDS in human hepatocytes, it is considered that the MOA for fluxapyroxad-induced liver tumour formation is qualitatively not plausible for humans.

Metabolites Study of Experimental Plant Derived Alkaloids: A Review

Abstract: Alkaloids are waste products of plant metabolic processes, containing at least one nitrogen atom in the heterocyclic ring. They serve a wide variety of physiological functions in humans and animals. Metabolism plays a central role in regulating the toxicity of various phytochemicals. Available literature of biological sources and metabolism study of pyrrolidine, pyrrolizidine, pyridine, quinoline, isoquinoline, phenanthrene, phenethylamine, indole, terpenoid, and aporphine groups of experimental plantsderived alkaloids were collected from the Google Scholar, PubMed/Medline, Science Direct, Scopus, Wiley Online Library, and Web of Science search engines. The literature reveals that hepatic microsomal enzymes such as monooxygenase and putative NADPH-FMN-reductase, carboxyl esterase, CYP2B6, CYP3A4, and CYP2D6 are primarily involved in the metabolism of alkaloids. This review may encourage natural product researchers to further research and develop new plant-derived alkaloidal drugs.

Gemcitabine enhances pharmacokinetic exposure of the major components of Danggui Buxue Decoction in rat via the promotion of intestinal permeability and down-regulation of CYP3A for combination treatment of non-small cell lung cancer

Context Danggui Buxue Decoction (DBD), a traditional Chinese medicine formula, has the potential to enhance the antitumor effect of gemcitabine in non-small cell lung cancer (NSCLC) treatment by increasing gemcitabine’s active metabolites. However, whether gemcitabine affects the pharmacokinetics of DBD’s major components remains unclear. Objective This study evaluates the herb–drug interaction between DBD’s major components and gemcitabine and validates the underlying pharmacokinetic mechanism. Materials and methods The pharmacokinetics of 3.6 g/kg DBD with and without a single-dose administration of 50 mg/kg gemcitabine was investigated in Sprague-Dawley rats. The effects of gemcitabine on intestinal permeability, hepatic microsomal enzymes in rat tissues, and CYP3A overexpressing HepG2 cells were determined using western blot analysis. Results The combination of gemcitabine significantly altered the pharmacokinetic profiles of DBD’s major components in rats. The C max and AUC of calycosin-7-O-β-d-glucoside notably increased through sodium-glucose transporter 1 (SGLT-1) expression promotion. The AUC of ligustilide and ferulic acid was also significantly elevated with the elimination half-life (t 1/2) prolonged by 2.4-fold and 7.8-fold, respectively, by down-regulating hepatic CYP3A, tight junction proteins zonula occludens-1 (ZO-1) and occludin expression. Discussion and conclusions Gemcitabine could modulate the pharmacokinetics of DBD’s major components by increasing intestinal permeability, enhancing transporter expression, and down-regulating CYP3A. These findings provide critical information for clinical research on DBD as an adjuvant for NSCLC with gemcitabine and help make potential dosage adjustments more scientifically and rationally.

Benoxacor is enantioselectively metabolized by microsomes and cytosol from the human liver

Benoxacor is a safener added to current-use herbicide formulations to protect the target crop from herbicidal toxicity. It is an emerging environmental contaminant that has been detected in surface waters, raising the possibility of human exposure via drinking water. Because it is not subject to the same regulations as active pesticide ingredients, its metabolism and toxicity in humans have not been studied. Here we investigate the enantioselective metabolism of benoxacor in human subcellular fractions. Pooled human liver microsomes (pHLM) and cytosol (pHLC) were incubated with racemic benoxacor for up to 30-min. Gas chromatographic analyses were used to measure the enantioselective depletion of benoxacor. pHLMs with and without nicotinamide adenine dinucleotide phosphate (NADPH, co-factor for cytochrome P450 enzymes [CYPs]) and pHLC with glutathione (GSH, co-factor for glutathione S-transferases [GSTs]) metabolized benoxacor. These results demonstrate that microsomal CYPs, microsomal carboxylesterase (CESs), and cytosolic GSTs metabolize benoxacor. Females were predicted to have a higher clearance of benoxacor by GSTs than males. Male and female pHLM incubations with NADPH showed enrichment of the first eluting benoxacor enantiomer (E1-benoxacor). pHLM incubations without NADPH and pHLC incubations with GSH showed an enrichment of the second eluting enantiomer of benoxacor (E2-benoxacor). Our results indicate that human hepatic microsomal and cytosolic enzymes enantioselectively metabolize benoxacor, a fact that needs to be considered when investigating human exposures and toxicities of benoxacor.

LBODP105 A Case of Significantly Increased Levothyroxine Requirement With Rifampin Therapy

Abstract Introduction Rifampin has a wide range of drug interactions through increased hepatic microsomal enzyme activity. We are reporting a case of a patient with post-surgical hypothyroidism on stable thyroid hormone replacement therapy who required significantly higher doses of levothyroxine after starting rifampin. Case Report Patient is a 78-year-old woman with history of Papillary Thyroid Cancer (PTC) in remission status post thyroidectomy in 1994 and radioactive iodine therapy in 1997. Patient had been on a stable dose of Levothyroxine of 75-88mcg daily until a visit in January 2013 when her TSH was found to be 39 despite compliance with levothyroxine. Further history revealed that she was diagnosed with Mycobacterium Avium Intracellulare (MAI) infection of the lungs for which she was given rifampin therapy. Her Levothyroxine dose was progressively increased to 150mcg daily. She received rifampin therapy for 18 months, from August 2012 until April 2013. Her Levothyroxine dose was later changed to average 139 mcg /day based on TSH levels and continued to be the same through the rifampin course. In April 2014, and following discontinuation of rifampin, Levothyroxine was decreased to 100mcg daily and subsequently 75mcg daily. During a relapse of MAI in March 2016, her levothyroxine dosage was similarly again increased to 125mcg daily for TSH of 24.58. In June 2017, rifampin was discontinued after completion of second course of MAI treatment, and Levothyroxine dose decreased to 88 mcg daily, and subsequently 75 mcg in September 2017, and average daily 64mcg most recently given age and long-term remission with target mid normal TSH. Discussion Rifampin is used to treat active tuberculosis and MAI infection among other uses. It is a hepatic enzyme inducer which significantly interacts with other drugs. It has been reported previously to cause hypothyroidism in patients with underlying thyroid disorder and increased serum TSH while on levothyroxine, but its impact range on thyroid function has not been clearly described. Our patient was on stable levothyroxine dose following thyroidectomy, and required almost a 100% increase of levothyroxine dose when started on rifampin therapy, returning to baseline levothyroxine requirements off rifampin. This case highlights the severe hypothyroidism and significant impact on levothyroxine dose requirements following rifampin therapy, and the importance of close thyroid function monitoring in patients with hypothyroidism and on rifampin, especially in context of post-surgical hypothyroidism. Presentation: No date and time listed

Dynamics of sex hormones in cows in the period of deep pregnancy and after calving in connection with hyperbilirubinemia

The article presents the results of comparing the level of sex hormones estradiol, progesterone and testosterone in cows with normal and elevated levels of bilirubin in the blood during deep pregnancy and immediately after calving. A study was carried out on 20 cows, which, according to the results of the concentration of bilirubin in after calving, were divided into two groups: the first group included 8 animals with an increased level of it, the second group included 12 animals with a normal content of bilirubin. It was determined that hyperbilirubinemia is accompanied by a significant increase in the level of progesterone by 45,2% and testosterone by 52,1% in the first week after calving in comparison with animals that do not have high concentrations of bilirubin in the blood. In the absence of statistically significant differences at the beginning of the observation period 15-20 days before calving, both in the concentration of bilirubin and in the content of sex steroids in the blood, 3-8 days before calving, an increase in the level of bilirubin, progesterone and testosterone in group 1 by 43,0%, 48,0% and 19,4% than in group 2. Since progesterone and testosterone are precursors of estradiol in the process of ovarian steroidogenesis, the revealed ratio of sex steroids in the studied cows may indicate, on the one hand, a violation biosynthesis of the most important estrogen estradiol in liver pathology, but on the other hand, this may be a consequence of a slowdown in the catabolism of progesterone and testosterone with the participation of hepatic microsomal enzymes and conjugation processes.

Treatment of epilepsy associated with primary and metastatic brain tumors

There is a number of unsolved issues in management of epilepsy associated with primary and metastatic brain tumors (BTs). In particular, no consensus approaches to treatment of patients with epilepsy associated with BTs have been proposed regarding use of current anti-epileptic drugs (AEDs). The review presents the relevant data on epidemiology, features of clinically manifested epilepsy at varying stages of BTs, aspects of drug-drug interaction between AEDs and anti-tumor agents, AED-related effects on cognitive functions as well as quality of life in patients with epilepsy associated with BTs. Levetiracetam and valproic acid comprise the first-line drugs for treating seizures in patients with BTs. It is unreasonable to use AEDs acting as hepatic microsomal enzyme inducers for therapy of epileptic seizures in BTs, because it may decrease efficacy of chemotherapy agents and glucocorticoids along with elevated rate of side effects. Perampanel acting as a selective noncompetitive AMPA receptor antagonist, may be one of the drugs of choice for the adjunctive therapy of epileptic seizures associated with BTs.

Inhibition of phase-1 biotransformation and cytostatic effects of diphenyleneiodonium on hepatoblastoma cell line HepG2 and a CYP3A4-overexpressing HepG2 cell clone.

Cell-based in vitro liver models are an important tool in the development and evaluation of new drugs in pharmacological and toxicological drug assessment. Hepatic microsomal enzyme complexes, consisting of cytochrome P450 oxidoreductase (CPR) and cytochrome P450 monooxygenases (CYPs), play a decisive role in catalysing phase-1 biotransformation of pharmaceuticals and xenobiotics. For a comprehensive understanding of the phase-1 biotransformation of drugs, the availability of well-characterized substances for the targeted modulation of in vitro liver models is essential. In this study, we investigated diphenyleneiodonium (DPI) for its ability to inhibit phase-1 enzyme activity and further its toxicological profile in an in vitro HepG2 cell model with and without recombinant expression of the most important drug metabolization enzyme CYP3A4.Aim of the study was to identify effective DPI concentrations for CPR/CYP activity modulation and potentially associated dose and time dependent hepatotoxic effects. The cells were treated with DPI doses up to 5,000nM (versus vehicle control) for a maximum of 48 h and subsequently examined for CYP3A4 activity as well as various toxicological relevant parameters such as cell morphology, integrity and viability, intracellular ATP level, and proliferation. Concluding, the experiments revealed a time- and concentration-dependent DPI mediated partial and complete inhibition of CYP3A4 activity in CYP3A4 overexpressing HepG2-cells (HepG2-CYP3A4). Other cell functions, including ATP synthesis and consequently the proliferation were negatively affected in both in vitro cell models. Since neither cell integrity nor cell viability were reduced, the effect of DPI in HepG2 can be assessed as cytostatic rather than cytotoxic.

Extraction of Ethyl-p-methoxycinnamate from Kaempferia galanga L.

In this study, ethyl-p-methoxycinnamate (EPMC) was extracted from Kaempferia galanga L. by different methods. The study results show that vacuum drying process led to a significant decrease in EPMC content in the herb (about 7%); EPMC obtained by water distillation not only had a high purity and yield but could also be applied for both fresh and dried herb; whereas, Soxhlet extraction with n-hexane solvent brought the highest extraction yield (1.99% on dried herb weight) despite lower purity when compared to that by water distillation method.
 Keywords
 Ethyl-p-methoxycinnamate, EPMC, Kaempferia galanga L., extraction.
 References
 [1] Botany Department, Botany, Hanoi University of Pharmacy, 2005 (In Vietnamese).[2] A. Kumar, Phytochemistry, pharmacological activities and uses of Indian traditional medicinal plant Kaempferia galanga L. – An overview, Journal of Ethnopharmacology (2020) 112667. https://doi.org/10.1016/j.jep.2020.112667.[3] H.J. Ko, H.J. Kim, S.Y. Kim, H.Y. Yun, K.J. Baek, N.S. Kwon, W.K. Whang, H.R. Choi, K.C. Park, D.S. Kim, Hypopigmentary Effects of Ethyl P‐Methoxycinnamate Isolated from Kaempferia galanga, Phytotherapy research 28(2) (2014) 274-279. https://doi.org/10.1002/ptr.4995.[4] M. Bonesi, J. Xiao, R. Tundis, F. Aiello, V. Sicari, M. R. Loizzo, Advances in the Tyrosinase Inhibitors from Plant Source, Current Medicinal Chemistry 26(18) (2019) 3279-3299. https://doi.org/10.2174/0929867325666180522091311.[5] M.I. Umar, M.Z. Asmawi, A. Sadikun, A.M. Majid, F.S. Al-Suede, L.E. Hassan, R. Altaf, M.B. Ahamed, Ethyl-p-methoxycinnamate isolated from Kaempferia galanga inhibits inflammation by suppressing interleukin-1, tumor necrosis factor-α, and angiogenesis by blocking endothelial functions, Clinics 69(2) (2014) 134-144. https://doi.org/10.6061/clinics/2014(02)10.[6] D. Lakshmanan, J. Werngren, L. Jose, K.P. Suja, M.S. Nair, R.L. Varma, S. Mundayoor, S. Hoffner, R.A. Kumar, Ethyl p-methoxycinnamate isolated from a traditional anti-tuberculosis medicinal herb inhibits drug resistant strains of Mycobacterium tuberculosis in vitro, Fitoterapia 82(5) (2011) 756-761. https://doi.org/10.1016/j.fitote.2011.03.006.[7] W. Sirisangtragul, B. Sripanidkulchai, Effects of Kaempferia galanga L. and ethyl-p-methoxycinnamate (EPMC) on hepatic microsomal cytochrome P450s enzyme activities in mice, J. Sci. Technol. 33(4) (2011) 411-417.[8] J. Wu, F. Ge, D. Wang, X. Xu, Combination of supercritical fluid extraction with high-speed countercurrent chromatography for extraction and isolation of ethyl p -methoxycinnamate and ethyl cinnamate from Kaempferia galanga L., Separation Science and Technology 51(10) (2016) 1757-1764. https://doi.org/10.1080/01496395.2016.1176046.[9] N. Srivastava, Ranjana, S. Singh, A.C. Gupta, K. Shanker, D.U. Bawankule, S. Luqman, Aromatic ginger (Kaempferia galanga L.) extracts with ameliorative and protective potential as a functional food, beyond its flavor and nutritional benefits, Toxicol Rep 6 (2019) 521-528. https://doi.org/10.1016/j.toxrep.2019.05.014.[10] I. Komalaa, Supandia, Nurhasnib, O.S. Bethaa, Yardia, S. Mufidaha, M. Rezaa, M.S. Alia, N.S. Auliaa, Sutara, Microwave Assisted Synthesis of p-Methoxycinnamamides and p-Methoxy-β-nitrostyrenes from Ethyl p-methoxycinnamate and Screening their Anti-inflammatory Activity, Natural Product Communications 12(8) (2017) 1265-1268.[11] Vietnamese Pharmacopoeia, the 5th edition, Appendix 2, (2017) (In Vietnamese)[12] AOAC International, AOAC official methods of analysis, Appendix K: Guidelines for Dietary Supplements and Botanicals, 2013.[13] P. Lunger, M. Weber, N. X. Dung, N. T. B. Tuyet, Ethyl p-Methoxycinnamate from Kaempferia galanga L. in Vietnam, Acta Cryst C52 (1996) 1255-1257. https://doi.org/10.1107/S0108270195016027.[14] S.K. Gupta, A.B. Banerjee, Achari B., Isolation of Ethyl p-methoxycinnamate, the major antifungal principle of Curcumba zedoaria, Curcumba zedoaria. Lloydia 39(4) (1976) 218-222.[15] M.I. Umar, M.Z. Asmawi, A. Sadikun, I.J. Atangwho, M.F. Yam, R. Altaf, A. Ahmed, Bioactivity-guided isolation of ethyl-p-methoxycinnamate, an anti-inflammatory constituent, from Kaempferia galanga L. extracts, Molecules 17(7) (2012) 8720-34. https://doi.org/10.3390/molecules17078720.

Metabolism of bifenthrin, β-cyfluthrin, λ-cyhalothrin, cyphenothrin and esfenvalerate by rat and human cytochrome P450 and carboxylesterase enzymes

The metabolism of bifenthrin (BIF), β-cyfluthrin (CYFL), λ-cyhalothrin (CYHA), cyphenothrin (CYPH) and esfenvalerate (ESF) was studied in liver microsomes, liver cytosol and plasma from male Sprague-Dawley rats aged 90, 21 and 15 days and from adult humans. Pyrethroid metabolism was also studied with some human expressed cytochrome P450 (CYP) and carboxylesterase (CES) enzymes. All five pyrethroids were metabolised by adult (90 day old) rat hepatic microsomal CYP and CES enzymes and by cytosolic CES enzymes. The pyrethroids were also metabolised by human liver microsomes and cytosol. Some species differences were observed. Pyrethroid metabolism by cytosolic CES enzymes contributes to the overall hepatic clearance of these compounds. CYFL, CYHA, CYPH and ESF were metabolised by rat plasma CES enzymes, whereas none of the pyrethroids were metabolised by human plasma. This study demonstrates that the ability of male rats to metabolise these pyrethroids by hepatic CYP and CES enzymes and plasma CES enzymes increases with age. In all instances, apparent intrinsic clearance values were lower in 15 than in 90 day old rats. All pyrethroids were metabolised by some of the human expressed CYP enzymes studied and apart from BIF were also metabolised by CES enzymes.

Stability of ten psychotropic drugs in formalin-fixed porcine liver homogenates

In forensic toxicology studies, drug concentrations must be estimated by the analytical data of formalin-fixed tissues if fresh or frozen tissue specimens are not available. We wished to investigate the stability and time-course of metabolism/degradation of drugs in formalin-fixed tissues using porcine liver homogenates (PLHs) instead of human tissue. Ten psychotropic drugs (amitriptyline, brotizolam, diazepam, diphenhydramine, estazolam, etizolam, levomepromazine, paroxetine, quetiapine and triazolam) were added to PLHs. After the PLHs had been fixed with neutral buffered formalin at room temperature, the concentrations of the drugs in the PLHs were determined by liquid chromatography–tandem mass spectrometry after 3 days, 1 week, 2 weeks, 4 weeks, 2 months, 4 months and 6 months. After 6 months, the residual ratio of amitriptyline, diphenhydramine and quetiapine was 80 %–95 %; that of diazepam, paroxetine and triazolam was 10 %–45 %; and that of brotizolam, etizolam and levomepromazine was 1 %–5 %. Estazolam was not detected from the first day of formalin fixation. These data suggest that the concentrations of drugs in PLHs measured after formalin fixation decreased to varying degrees compared with their initial concentrations. These time-dependent changes in drug concentration were due to degradation during preservation in formalin solution and metabolism by hepatic microsomal enzymes.

Evaluation of days-dependent chloramphenicol dosage on rat liver microsomal lipid peroxidation and catalase activity

Drugs and chemical agents can alter the cellular functions associated with the oxidative metabolism, thereby stimulating ROS production. The objective of the this study was the in vivo study of the inhibitory effect of chloramphenicol on hepatic microsomal enzyme system and the effect on lipid peroxidation using the thiobarbituric acid (TBA) reactive as index of peroxidation damage was investigated. The rats were randomly divided into 3 groups; group 1 serves as the control receiving saline water, group 2 receive chloramphenicol at a dose of 28.6 mg/kg body weight/day for 5 days and group 3 for 7 days. Liver protein content, lipid hydroperoxides and catalase activity were all determined. TBARS concentration increased statistically significantly with time of exposure. After 5 days of treatment, the level of TBARS increased by 103.56% with exogenous oxidant and by 141.54% for without oxidant, as compared to the respective control. On day 7, TBARS level in the liver was approximately 90.75% higher than in the control group with oxidant and 117.03% higher than the control without oxidant. The antibiotic elicited significant increase in rat liver lipid peroxidation compared to control. There were decreases in microsomal protein content of the liver in the drug-treated rats when compared with the control rats. It also showed that chloramphenicol treatment affects cytosolic catalase activities. It decreases catalase levels by 15.75% in 5 days dosage treatment and 17.81% in 7 days dosage treatment respectively. There were significance difference (P<0.05) in the treated and control irrespective of the days of dosage. The catalase level in hepatocyte in 5 days and 7 days group was significance at p<0.01. In conclusion, it was evident that treatment of rats for 5 days and 7 days with the therapeutic doses of Chloramphenicol altered antioxidant system and the intensity of effects was concentration/dosage days dependent, it resulted in membrane lipid peroxidation, protein damage, and inhibition of microsomal catalase due to increased generation of free radicals, reactive oxygen species and reactive nitrogen speciesKeywords: Chloramphenicol, rat liver, lipid peroxidation, catalase activity, antioxidant

MON-355 Recurrent Adrenal Crisis Secondary to Rifampin-Induced Hepatic Microsomal Enzyme Metabolism

Rifampin is a widely known antibiotic used to treat several types of bacterial infections including tuberculosis (TB) in a combination therapy setting. Rifampin is also known to have a profound drug-drug interaction profile. We describe here a case of rifampin induced hepatic microsomal enzyme causing accelerated hydrocortisone metabolism in a patient with panhypopituitarism resulting in multiple admissions with adrenal crisis. This is a 73-year-old male with a history of pituitary sarcoidosis since the 1980s with subsequent panhypopituitarism requiring replacement with levothyroxine, testosterone, desmopressin, and hydrocortisone in a stable dose pattern of 15 mg in the morning and 5 mg in the evening. He had been recently started on multi-drug therapy for military TB in the setting of an iliopsoas abscess. Initial therapy consisted of the following drug combination: rifampin, isoniazid, pyrazinamide, and ethambutol. After initiation of TB therapy, he presented with signs and symptoms of adrenal crisis that included: fatigue, hypotension, hyponatremia, hyperkalemia, and metabolic acidosis. Despite attempts at increasing the hydrocortisone dose over multiple hospital admissions, the patient had recurrent admissions for adrenal crisis episodes. These events occurred despite changes in his TB therapy regimen (therapy changed to rifampin and levofloxacin followed by the addition of meropenem, Augmentin and cycloserine for suspected resistant TB). Eventually, a stable dose of hydrocortisone 80 mg daily divided into 40/40 mg in the morning and evening stabilized the patient with no further adrenal crisis episodes. Rifampin is considered to be the most powerful known inducer of the hepatic cytochrome P450 enzyme system. It is known to increase the metabolism of many drugs that leads to those drugs being partially or totally ineffective. The list of drugs influenced by this mechanism includes: warfarin, contraceptive pills, anti-retroviral therapy, statins and many more.1 In addition, case reports have been described of hypothyroid patients requiring significantly higher doses of thyroid hormone replacement while on rifampin as compared to their original weight-based dosing requirements. However, in the literature, rifampin inducing increased steroid replacement therapy requirements in adrenally insufficient patients has been rarely reported. This case illustrates the need for increased awareness of higher steroid dose requirements, namely hydrocortisone, in patients on steroid replacement therapy with concomitant use of rifampin to avoid the sequelae of adrenal crisis which can be life threatening. 1. Hardman, Joel G., Lee E. Limbird, and Alfred G. Gilman, eds. "Rifampin." The Pharmacological Basis of Therapeutics. 10th ed. United States of America: The McGraw-Hill Companies, 2001. pp. 1277-1279.

Managing a side effect: Cyclophosphamide-induced hemorrhagic cystitis

Cyclophosphamide is a nonphase-specific cytotoxic agent that can kill cells at any phase of the cell cycle. The drug is metabolized by hepatic cytochrome P450 microsomal enzymes, which results in the formation of the active metabolites phosphoramide mustard and acrolein. It is the acrolein which is responsible for hemorrhagic cystitis as a complication of cyclophosphamide therapy. An early diagnosis and prompt management holds the key in its management.

The effects on the endocrine system under hepatotoxicity induction by phenobarbital and di(2-ethylhexyl)phthalate in intact juvenile male rats

Phenobarbital (PB) and Di (2-ethylhexyl) phthalate (DEHP), an anti-epileptic drug and a plasticizer used in flexible polyvinylchloride formulations, respectively, are well-known typical hepatotoxicants. This study investigated the effects of PB (100 mg/kg/day) or DEHP (500 mg/kg/day) on the endocrine system in intact juvenile/peripubertal male rats exposed for 31 days beginning on postnatal day 23. Slight hormone level changes, histopathological changes in thyroid gland or induction of UDP-glucuronosyltransferase in liver were observed in both the PB and DEHP groups. One of the assumed mechanisms inducing thyroid effects is predictable to be secondary changes based on the enhancement in thyroid hormone metabolism via the induction of hepatic microsomal enzymes. No reproductive system-related changes in organ weights, histopathology, and sexual maturation were observed in both groups. Lower testosterone level was observed in the PB group. CYP2B and CYP3A, which are involved in testosterone metabolism, were induced in liver of the PB group. There was no change of 17β-hydroxysteroid dehydrogenase activity in testis of both groups. Lower testosterone level in the PB-treated male rats was attributed to an indirect, hepatotoxicity-associated effect on the reproductive system and not to direct effects on testis such as the antiandrogenic activity and the inhibition of steroidogenesis. These results did not indicate that PB or DEHP exposure affects the endocrine system directly.

Pharmacokinetic differences of mifepristone between sexes in animals

Mifepristone (RU486) is developed originally as a contraceptive used by hundreds of millions of women world-wide, and also reported as a safe and long-term psychotic depressant, or as a cancer chemotherapeutic agent used by both sexes. In our preliminary study aimed at developing mifepristone as a cancer metastatic chemopreventive, we coincidentally observed that blood mifepristone concentrations in female rats seem to be higher than those in male ones post administration. To substantiate if the pharmacokinetic differences between sexes exist, we established a fast UPLC–MS/MS method to determine mifepristone concentrations in plasma, and analyzed blood concentrations of mifepristone over time in rats and dogs of both sexes. Mifepristone in plasma or incubation liquid was recovered by liquid-liquid extraction using 1mL of ethyl acetate. Chromatographic separation was performed on a C18 column at 35°C, with a gradient elution consisting of methanol and water containing 0.1% (v/v) formic acid at a flow rate of 0.3mL/min. And pharmacokinetic parameters such as elimination half-life, and mean residence time were calculated by using the non-compartmental pharmacokinetics data analysis software. In this work, administrations of mifepristone to rats and beagle dogs revealed that the plasma concentrations of mifepristone (AUC, Cmax) were significantly higher (P<0.05) in females than that in males. In vitro liver microsomal incubation experiments showed that the metabolic rate of mifepristone in males was higher than that in females, which was consistent with the results of in vivo experiments. In general, we first found the sex-related differences about pharmacokinetic properties of mifepristone and revealed the metabolism difference of hepatic microsomal enzyme is the main reason.

Alkynyl-containing phenylthiazoles: Systemically active antibacterial agents effective against methicillin-resistant Staphylococcus aureus (MRSA)

The promising activity of phenylthiazoles against multidrug-resistant bacterial pathogens, in particular MRSA, has been hampered by their limited systemic applicability, due to their rapid metabolism by hepatic microsomal enzymes, resulting in short half-lives. Here, we investigated a series of phenylthiazoles with alkynyl side-chains that were synthesized with the objective of improving stability to hepatic metabolism, extending the utility of phenylthiazoles from topical applications to treatment of a more invasive, systemic MRSA infections. The most promising compounds inhibited the growth of clinically-relevant isolates of MRSA in vitro at concentrations as low as 0.5 μg/mL, and exerted their antibacterial effect by interfering with bacterial cell wall synthesis via inhibition of undecaprenyl diphosphate synthase and undecaprenyl diphosphate phosphatase. We also identified two phenylthiazoles that successfully eradicated MRSA inside infected macrophages. In vivo PK analysis of compound 9 revealed promising stability to hepatic metabolism with a biological half-life of ∼4.5 h. In mice, compound 9 demonstrated comparable potency to vancomycin, and at a lower dose (20 mg/kg versus 50 mg/kg), in reducing the burden of MRSA in a systemic, deep-tissue infection, using the neutropenic mouse thigh-infection model. Compound 9 thus represents a new phenylthiazole lead for the treatment of MRSA infections that warrants further development.

The role of acid-base imbalance in statin-induced myotoxicity

Disturbances in acid-base balance, such as acidosis and alkalosis, have potential to alter the pharmacologic and toxicologic outcomes of statin therapy. Statins are commonly prescribed for elderly patients who have multiple comorbidities such as diabetes mellitus, cardiovascular, and renal diseases. These patients are at risk of developing acid-base imbalance. In the present study, the effect of disturbances in acid-base balance on the interconversion of simvastatin and pravastatin between lactone and hydroxy acid forms have been investigated in physiological buffers, human plasma, and cell culture medium over pH ranging from 6.8–7.8. The effects of such interconversion on cellular uptake and myotoxicity of statins were assessed in vitro using C2C12 skeletal muscle cells under conditions relevant to acidosis, alkalosis, and physiological pH. Results indicate that the conversion of the lactone forms of simvastatin and pravastatin to the corresponding hydroxy acid is strongly pH dependent. At physiological and alkaline pH, substantial proportions of simvastatin lactone (SVL; ∼87% and 99%, respectively) and pravastatin lactone (PVL; ∼98% and 99%, respectively) were converted to the active hydroxy acid forms after 24 hours of incubation at 37°C. At acidic pH, conversion occurs to a lower extent, resulting in greater proportion of statin remaining in the more lipophilic lactone form. However, pH alteration did not influence the conversion of the hydroxy acid forms of simvastatin and pravastatin to the corresponding lactones. Furthermore, acidosis has been shown to hinder the metabolism of the lactone form of statins by inhibiting hepatic microsomal enzyme activities. Lipophilic SVL was found to be more cytotoxic to undifferentiated and differentiated skeletal muscle cells compared with more hydrophilic simvastatin hydroxy acid, PVL, and pravastatin hydroxy acid. Enhanced cytotoxicity of statins was observed under acidic conditions and is attributed to increased cellular uptake of the more lipophilic lactone or unionized hydroxy acid form. Consequently, our results suggest that comorbidities associated with acid-base imbalance can play a substantial role in the development and potentiation of statin-induced myotoxicity.

Ritonavir Use in Human Immunodeficiency Virus–Positive Surgical Patients Is Not Associated with an Increase in Postoperative Critical Respiratory Events

ABSTRACTThis study evaluated whether highly active antiretroviral therapy for human immunodeficiency virus (HIV) including ritonavir is independently associated with increased critical respiratory events after general anesthesia with opioid analgesia. The impact of ritonavir on hepatic microsomal enzymes was considered due to the effect of these enzymes on opioid metabolism. Medical records of over 1900 patients were reviewed, and those of 941 patients met inclusion criteria and were analyzed. Chronic treatment with ritonavir was not associated with critical respiratory events in HIV-positive patients.